L.M. KUPKENOVA¹, D.I. ABDULGANIEVA^1,2, N.G. SHAMSUTDINOVA¹, A.KH. ODINTSOVA², D.G. ISKHAKOVA³, M.I. CHERKASHINA², N.A. CHEREMINA²

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

³City Clinical Hospital No. 7, Kazan

Contact details:

Kupkenova L.M. — post-graduate student of the Department of Hospital Therapy

Address: 138A Orenburgskiy trakt, Kazan, Russian Federation, 420064, tel.: +7-917-901-14-98, e-mail: lkupkenova@mail.ru

 The purpose — to assess the presence and course of post-COVID syndrome, damage to the lungs and cardiovascular system, as well as the course of IBD in the post-COVID period.

Material and methods. The study included 36 patients diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) who had COVID-19 with lung damage. To identify the clinical symptoms characteristic of the post-COVID syndrome, we used a questionnaire as part of an in-depth medical examination for citizens who had had COVID-19 3, 6, 9 and 12 months before. All patients, 12 months after having COVID-19, underwent an assessment of the respiratory function (RF), echocardiography, and X-ray computed tomography of the chest organs (CT scan of the chest).

Results. Complaints characteristic of post-COVID syndrome occurred more often and longer in patients with respiratory distress (RD). When assessing the respiratory function and echocardiography, minor changes were detected; in the group of patients with RD, the changes were more pronounced. When analyzing the parameters of the CT scan of the chest after 12 months, changes were detected only in the group of patients with RD during COVID-19. The maximum number of patients in exacerbation of IBD was noted 3-6 months after COVID-19.

Conclusions. According to the results of the questionnaire used as part of the in-depth medical examination of patients after COVID-19, respiratory function, echocardiography, CT scan, it was found that the post-COVID syndrome was more severe and lasted longer in patients with lung damage and RD during COVID-19.

Key words: IBD, post-COVID syndrome, COVID-19.

REFERENCES

1. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C. et al. Post-acute COVID-19 syndrome. Nat Med, 2021, vol. 27 (4), pp. 601–615. DOI: 10.1038/s41591-021-01283-z
2. Pan F., Yang L., Liang B., Ye T., Li L., Li L., Liu D., Wang J. et al. Patterns from Diagnosis to 1 Year of Follow-up in Patients with COVID-19. Radiology, 2022, vol. 302 (3), pp. 709–719. DOI: 10.1148/radiol.2021211199
3. Baryshnikova G.A., Chorbinskaya S.A., Zimina T.A., Stepanova I.I., Kudryavtseva N.A. COVID-19: the place of metabolism correctors in the treatment of patients with post-COVID syndrome. Lechashchiy vrach, 2022, vol. 3 (25), pp. 80–86 (in Russ.). DOI: 10.51793/OS.2022.25.3.013
4. Liao T., Meng D., Xiong L., Wu S., Yang L., Wang S., Zhou M., He X. et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan. Infect Dis Ther, 2022, vol. 11 (1), pp. 145–163. DOI: 10.1007/s40121-021-00553-0
5. Panchenko D.I., Kanorskiy S.G., Bystrov A.O., Moysova D.L., Gorodin V.N., Ionov A.Yu. Clinical and echocardiographic changes in patients with COVID-19, 6 months after discharge from the hospital. Sovremennye problemy nauki i obrazovaniya, 2022, no. 2 (in Russ.), available at: https://science-education.ru/ru/article/view?id=31633 (accessed on: 17.03.2023)
6. Abakushina E.V. Immunological aspects of coronavirus disease caused by SARS-COV-2. Geny i kletki, 2020, no. 3 (in Russ.), available at: https://cyberleninka.ru/article/n/immunologicheskie-aspekty-koronavirusnoy-bolezni-vyzvannoy-sars-cov-2 (accessed on: 12.03.2023)
7. Chen L., Hu K., Cheng C., Hu Q., Zhang L., An T., Guo Y., Chen S., Duan G. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Colorectal Dis, 2022, vol. 37 (11), pp. 2277–2289. DOI: 10.1007/s00384-022-04265-w
8. Salvatori S., Baldassarre F., Mossa M., Monteleone G. Long COVID in Inflammatory Bowel Diseases. J Clin Med, 2021, vol. 10 (23), p. 5575. DOI: 10.3390/jcm10235575
9. Attauabi M., Dahlerup J.F., Poulsen A., Hansen M.R. et al. Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases — A Danish Prospective Population-Based Cohort Study with Individual-Level Data. J Crohns Colitis, 2022, vol. 16 (5), pp. 757–767. DOI: 10.1093/ecco-jcc/jjab192
10. Wetwittayakhlang P., Albader F., Golovics P.A., Hahn G.D. et al. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol, 2021, p. 7591141. DOI: 10.1155/2021/7591141
11. Best W.R., Becktel J.M., Singleton J.W., Kern F.Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 1976, vol. 70 (3), pp. 439–444.
12. Truelove S.C. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. British Medical Journal, 1954, vol. 2, pp. 375–378.
13. Vremennye metodicheskie rekomendatsii: profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19), versiya 16 (18.08.2022) [Interim Guidelines: Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19), version 16 (08/18/2022)].
14. Prikaz MZ RF ot 1.07.2021 no. 698n “Ob utverzhdenii Poryadka napravleniya grazhdan na prokhozhdenie uglublennoy dispanserizatsii, vklyuchaya kategorii grazhdan, prokhodyashchikh uglublennuyu dispanserizatsiyu v pervoocherednom poryadke” (zaregistrirovan 7.07.2021 no. 64157) [Order of the Ministry of Health of the Russian Federation of July 1, 2021 No. 698n “On approval of the Procedure for sending citizens to undergo in-depth medical examination, including categories of citizens undergoing in-depth medical examination as a matter of priority” (registered on July 7, 2021 No. 64157)].
15. Bustamante S., Yau Y., Boys V., Chang J., Paramsothy S. et al. Tryptophan Metabolism ‘Hub’ Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel Disease. Int J Mol Sci, 2022, vol. 23 (23), p. 14776. DOI: 10.3390/ijms232314776
16. Giron L.B., Dweep H., Yin X., Wang H., Damra M., Goldman A.R. et al. Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. Front Immunol, 2021, vol. 12, p. 686240. DOI: 10.3389/fimmu.2021.686240
17. Chernyak A.V., Savushkina O.I. Spirometry study in clinical practice. Byul. fiz. i pat. dykh, 2020, no. 77 (in Russ.), available at: https://cyberleninka.ru/article/n/spirometricheskoe-issledovanie-v-klinicheskoy-praktike (accessed on: 19.03.2023)/
18. Rosa I., Conti C., Zito L., Efthymakis K., Neri M., Porcelli P. Has the COVID-19 Pandemic Worsened Health-Related Quality of Life of Patients with Inflammatory Bowel Disease? A Longitudinal Disease Activity-Controlled Study. Int J Environ Res Public Health, 2023, vol. 20 (2), p. 1103. DOI: 10.3390/ijerph20021103